HR-7970-119
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 21.
Sponsored by Robert Latta (R-OH)
What it does
This bill would permanently add nitazenes — a class of synthetic opioids known chemically as 2-benzylbenzimidazole opioids — to Schedule I of the Controlled Substances Act. It would cover not just specific named nitazene compounds but also any structurally related substances that act on the mu-opioid receptor, using a broad chemical definition. The bill would also convert any nitazenes currently under temporary scheduling to permanent Schedule I status, and would require the Attorney General to issue implementing rules within one year, which may take effect immediately as interim final rules.
Who benefits
Law enforcement agencies, who would gain permanent and broader legal authority to prosecute nitazene trafficking without relying on temporary scheduling orders. Communities and families affected by synthetic opioid overdoses, who may see reduced availability of these substances. Emergency medical personnel and public health agencies, who would have clearer legal classification for these drugs. Drug treatment and harm reduction organizations, who could more easily access federal resources tied to Schedule I enforcement. Pharmaceutical companies developing legitimate opioid alternatives, who face less competition from illicit nitazene analogs.
Who is hurt
Researchers and scientists studying nitazene compounds for potential medical applications, who would face the significant regulatory barriers that apply to Schedule I substances. Pharmaceutical developers who might otherwise pursue nitazenes as pain management treatments, since Schedule I classification makes clinical trials more difficult and costly. Criminal defendants who may face mandatory minimum sentences under Schedule I penalties. Individuals who use these substances and may be driven further underground, potentially reducing access to harm reduction services. Defense attorneys and civil liberties advocates who argue broad analog-style definitions create legal uncertainty about which substances are covered.
Supporters argue
Supporters argue that nitazenes are among the most dangerous synthetic opioids ever identified — some compounds are estimated to be 10 to 100 times more potent than fentanyl — and that their rapid proliferation in the illicit drug supply has contributed to a surge in overdose deaths. They contend that temporary scheduling orders are inadequate because they expire and require repeated renewal, creating enforcement gaps that traffickers exploit by introducing slightly modified analogs. The bill's broad structural definition, they argue, is specifically designed to close the "designer drug" loophole that has allowed chemists to evade existing law by making minor molecular changes.
Opponents argue
Opponents argue that permanently scheduling an entire chemical class under Schedule I — rather than evaluating each compound individually — bypasses the scientific review process established by the Controlled Substances Act, which requires findings on medical utility and abuse potential before scheduling. They contend that the bill's sweeping structural definition, which covers any substance with mu-opioid receptor activity, is so broad it could inadvertently capture compounds with legitimate medical potential or create prosecutorial ambiguity. Critics also argue that Schedule I classification has historically failed to reduce drug availability while imposing severe criminal penalties that fall disproportionately on low-income and minority communities.